← Back to Search

Behavioral Intervention

Digital Therapeutics for Cognitive Decline

N/A
Recruiting
Led By David Ziegler, PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
60+ years old (adult)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, immediate follow-up, and at a 6 month follow-up
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to find the right amount of a digital intervention that can improve cognitive function. Researchers will also study how factors like cognitive decline, genetic risk for Alzheimer's, heart health, and race can

Who is the study for?
This trial is for adults over the age of 60 who speak English and own a smartphone or tablet. It's aimed at those experiencing cognitive impairment, aging-related memory issues, or mild cognitive decline.
What is being tested?
The study tests two digital programs: MediTrain and Worder. They're designed to enhance attention and wellbeing in older adults. The research will determine how much treatment is needed for cognitive improvement and explore factors that might influence its effectiveness.
What are the potential side effects?
Since this trial involves digital interventions rather than medications, traditional side effects are not expected. However, participants may experience eye strain or mental fatigue from using their devices.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 60 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, immediate follow-up, and at a 6 month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, immediate follow-up, and at a 6 month follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change on the Mobile Continuous Performance Task (CPT) over time
Secondary study objectives
Change on the Adaptive Cognitive Evaluation (ACE) over time
Other study objectives
Mean Change on Cognitive Failures Questionnaire
Mean Change on Emotional Regulation Questionnaire
Mean Change on Everyday Cognition Scale (ECog)
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: MediTrain 30m/day for 6wksExperimental Treatment1 Intervention
Participants will engage with a digital meditation app for the time listed above.
Group II: MediTrain 30m/day for 3wksExperimental Treatment1 Intervention
Participants will engage with a digital meditation app for the time listed above.
Group III: MediTrain 15m/day for 6wksExperimental Treatment1 Intervention
Participants will engage with a digital meditation app for the time listed above.
Group IV: MediTrain 15m/day for 3wksExperimental Treatment1 Intervention
Participants will engage with a digital meditation app for the time listed above.
Group V: Active Control GroupActive Control1 Intervention
An active control application will be used for this arm. The total training experience here will be for 6 weeks (5 days/week), with each training session lasting \~30 minutes (not including self-paced breaks). Here an app that is matched in terms of expectancy of benefits compared to our training groups will be determined by questioning 100 naïve individuals to predict their expected improvement on each cognitive domain across a multitude of possible applications.

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,580 Previous Clinical Trials
15,173,500 Total Patients Enrolled
11 Trials studying Aging
712 Patients Enrolled for Aging
National Institute on Aging (NIA)NIH
1,782 Previous Clinical Trials
28,180,093 Total Patients Enrolled
173 Trials studying Aging
76,803 Patients Enrolled for Aging
David Ziegler, PhDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
180 Total Patients Enrolled
2 Trials studying Aging
180 Patients Enrolled for Aging
~2667 spots leftby Jun 2029